Wave Life Sciences has announced an amendment to its ongoing collaboration with Takeda which immediately discontinues further discovery collaboration. Takeda is retaining the option to co-develop and co-commercialize Wave’s late-stage CNS programs.
The two companies formed a global alliance in early 2018 to discover, develop and commercialize Wave's stereopure oligonucleotides for central nervous system disorders.
The headline US$2bn deal, which included an upfront of US$110m and equity stake of US$60m, included programs in Huntington's disease, ALS, frontotemporal dementia and spinocerebellar ataxia type 3, as well as a handful of preclinical CNS programs.
The decision by Takeda to end the discovery collaboration comes several months after two of Wave’s experimental drug candidates failed in clinical trials on Huntington’s disease.
https://finance.yahoo.com/news/wave-life-sciences-takeda-discontinue-105452038.html
https://endpts.com/takeda-wave-life...30m-rd-collaboration-dropping-discovery-work/
https://hotcopper.com.au/threads/an...4733386/page-82?post_id=39286798#.YW9HrhoRWUk
https://hotcopper.com.au/threads/an...5118769/page-12?post_id=42040171#.YW9IKBoRWUk
Ann: Drug Delivery Greater Than 100% More Effective - Amended, page-34
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PYC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
14.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $676.5M | |||
| Open | High | Low | Value | Volume |
| 14.0¢ | 14.5¢ | 13.5¢ | $687.7K | 4.887M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 87494 | 14.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 15.0¢ | 2187900 | 13 |
View Market Depth
| Last trade - 16.10pm 13/09/2024 (20 minute delay) ? |
| PYC (ASX) Chart |